Drug profile · INN
luspatercept-aamt
REBLOZYL
luspatercept-aamt (REBLOZYL) is a transforming growth factor beta inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — luspatercept-aamt
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
luspatercept-aamt (REBLOZYL) is a transforming growth factor beta inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Transforming growth factor beta inhibitor
Primary target: Transforming growth factor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is luspatercept-aamt?
luspatercept-aamt (REBLOZYL) is a transforming growth factor beta inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for luspatercept-aamt?
REBLOZYL is a marketed brand name for luspatercept-aamt. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of luspatercept-aamt?
luspatercept-aamt has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.